Pathobiology research at EORTC aims to identify and validate biomarkers across cancer types that can be used to develop new or more targeted treatments.

Main Achievements

EORTC has implemented a cross group policy for biobanking

EORTC research has resulted in the clinical qualification of uPA/PAI-1 as a class 1 level-of-evidence biomarkers for the prognosis of node-negative breast cancer patients. These biomarkers were subsequently recommended by national and international guidelines.

It has also contributed to the validation of gene-expression profiles and to the discovery of mechanisms of breast cancer metastasis leading to more personalised treatment for this cancer.

In addition, our pathobiology research has guided the development of robust, reliable and cost-effective assays applicable for routine clinical testing.

Related Projects

  • Cancer-ID: a European consortium that aims to establish standard protocols and clinical validation of blood-based biomarkers
  • SPECTA: the pathobiology group is ensuring quality control for all aspects of Human Biological Material for the EORTC molecular screening platform

Research Group

  • Chair

    Ira Skvortsova

    Innsbruck Universitaetsklinik

    Innsbruck, Austria

  • Secretary

    Leticia Oliveira-Ferrer

    UKE - University Cancer Center

    Hamburg, Germany

  • Treasurer

    Maurizio Callari

    Cruk Cambridge Institute

    Cambridge , United Kingdom